Clinical Trial Update: Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of sorafenib tosylate in locally advanced, metastatic, or locally recurrent thyroid cancers was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Cancer
• Follicular Thyroid Cancer
• Insular Thyroid Cancer
• Papillary Thyroid Cancer
• Thyroid Cancer

Drugs mentioned

• Sorafenib tosylate (sorafenib tosylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anaplastic Thyroid Cancer, Insular Thyroid Cancer | Phase 2 | Status: TERMINATED